PMID- 23700053
OWN - NLM
STAT- MEDLINE
DCOM- 20140220
LR  - 20130523
IS  - 1439-3824 (Electronic)
IS  - 0300-8630 (Linking)
VI  - 225 Suppl 1
DP  - 2013 May
TI  - Cytogenetic aspects of childhood leukemias.
PG  - S30-3
LID - 10.1055/s-0033-1337960 [doi]
AB  - Recurrent non-random chromosome abnormalities, including numerical or structural 
      changes such as translocations, inversions, insertions or deletions within the 
      leukemia cell nucleus, have been discovered in approximately 80% of patients with 
      a malignant hematological disease. These reciprocal translocations correlate with 
      specific cellular subtypes of hematopoeisis at the stage of their maturation 
      arrest and are therefore important for diagnosis. Some of these aberrations are 
      independent prognostic indicators and help to stratify patients into different 
      risk-adapted therapy groups. Owing to new laboratory methods such as the 
      fluorescence in situ hybridization (FISH) and modified polymerase chain reaction 
      (RT-PCR) the chromosomal breakpoints can be investigated and the rearrangements 
      of genes which produce the abnormal proteins can be identified. Due to the high 
      sensitivity of these available data a new prognostic factor, the "minimal 
      residual disease" (MRD), can be investigated at diagnosis and at intervals during 
      the treatment period. Since we now know which oncoproteins are involved, a 
      target-directed therapy with inhibitors might be possible in the future.Standard 
      cytogenetic and molecular genetic analysis of the leukemia karyotype is of the 
      utmost importance for classification (WHO), therapy and therapy results in the 
      acute childhood leukemias.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Lampert, F
AU  - Lampert F
AD  - Department of General Pediatrics, Hematology and Oncology, Justus Liebig 
      University, Giessen, Germany. Fritz.H.Lampert@paediat.med.uni-giessen.de
FAU - Harbott, J
AU  - Harbott J
FAU - Borkhardt, A
AU  - Borkhardt A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130522
PL  - Germany
TA  - Klin Padiatr
JT  - Klinische Padiatrie
JID - 0326144
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Child
MH  - *Chromosome Aberrations
MH  - Chromosome Breakage
MH  - Drug Delivery Systems
MH  - Gene Rearrangement/genetics
MH  - Hematopoiesis/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia/classification/diagnosis/drug therapy/*genetics
MH  - Neoplasm, Residual/diagnosis/genetics
MH  - Prognosis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Translocation, Genetic/*genetics
EDAT- 2013/05/24 06:00
MHDA- 2014/02/22 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/24 06:00 [entrez]
PHST- 2013/05/24 06:00 [pubmed]
PHST- 2014/02/22 06:00 [medline]
AID - 10.1055/s-0033-1337960 [doi]
PST - ppublish
SO  - Klin Padiatr. 2013 May;225 Suppl 1:S30-3. doi: 10.1055/s-0033-1337960. Epub 2013 
      May 22.